NetScientific plc

Equities

NSCI

GB00BN4R5Q82

Investment Management & Fund Operators

Market Closed - London S.E. Other stock markets 16:35:06 20/05/2024 BST			5-day change	1st Jan Change
69 ^GBX	0.00%		+6.98%	+15.00%

05-15	Vertu Motors ups dividend as hails record revenue	AN
05-13	EARNINGS AND TRADING: itim loss narrows; Vela trims EnSilica stake	AN

NetScientific says PDS Biotech's Versamune meets endpoints

May 10, 2024 at 01:20 pm

NetScientific PLC - London-based deep tech and life sciences venture capital investor - Says its portfolio company, PDS Biotechnology Corp's Versamune meets endpoints in a phase three trial for patients with HPV. NetScientific holds a 3.5% shareholding in PDS. Versamune is a T cell-activating platform that effectively stimulates a precise immune system response to a cancer-specific protein.

Current stock price: 62.39 pence, down 0.2%

12-month change: down 16%

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
PDS LIMITED	422.4 INR	-0.62%	-3.87%	670M
NETSCIENTIFIC PLC	69 GBX	0.00%	+6.98%	20.99M
PDS BIOTECHNOLOGY CORPORATION	3.28 USD	-6.02%	-8.50%	128M

Latest news about NetScientific plc

Vertu Motors ups dividend as hails record revenue	05-15	AN
EARNINGS AND TRADING: itim loss narrows; Vela trims EnSilica stake	05-13	AN
Netscientific Unit Agrees to Manage Martlet Capital’s GBP23 Million Portfolio	05-13	MT
NetScientific says PDS Biotech's Versamune meets endpoints	05-10	AN
Netscientific's ProAxsis Secures Investment for Product Development	04-15	MT
NetScientific investee secures funding to develop product range	04-15	AN
Empire Metals targets key milestones in Australia	03-27	AN
NetScientific "significantly" advances strategic goals	03-13	AN
Esken's Southend Airport faces further allegations	01-23	AN
Netscientific's Glycotest Receives $1 Million Investment from Fosun	01-23	MT
Glycotest, Inc. announced that it has received $1 million in funding from EMV Capital Ltd, NetScientific plc, Shanghai Fosun Pharmaceutical Co., Ltd.	01-22	CI
NetScientific's DeepTech Recycling Closes GBP1 Million Fundraising	12-01	MT
NetScientific investee DeepTech Recycling bags GBP1 million	12-01	AN
NetScientific's portfolio company updates on cancer trial	11-09	AN
Pds Biotech Announces Updated Survival Data from Nci-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients	11-09	CI
NetScientific's EMV Leads Investment Round in Portfolio Company Ventive	11-06	MT
NetScientific investee claims promising results in biomarker study	23/10/23	AN
NetScientific portfolio company updates on cancer trial	03/10/23	AN
EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens	28/09/23	AN
Earnings Flash (NSCI.L) NETSCIENTIFIC Posts H1 Revenue GBP770,000	28/09/23	MT
NetScientific plc Reports Earnings Results for the Half Year Ended June 30, 2023	28/09/23	CI
NetScientific's Q-Bot completes GBP3.5 million investment programme	13/09/23	AN
NetScientific's PDS suffers wider loss as R&D costs mount	14/08/23	AN
Pendragon quarterly trading momentum maintained	30/06/23	AN
DName-iT NV announced that it has received Â£0.5 million in funding from NetScientific plc, EMV Capital Ltd, KBC Group NV, BNP Paribas Fortis SA and other investors	29/06/23	CI

Chart NetScientific plc

Duration

Period

More charts

Company Profile

NetScientific plc is a United Kingdom-based deep tech and life sciences venture capital (VC) investment group with an international portfolio of innovative companies. The Company identifies, invests in, and builds high growth companies in the United Kingdom and internationally. It employs a capital-light investment approach, making use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital Limited. The Company secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a structure that can support a large portfolio. Its portfolio consists of a combination of direct investments and capital under advisory (CUA). The Company has about 24 portfolio companies with a focus on life sciences, technology, and sustainability. The Company's subsidiaries include EMV Capital Limited, Glycotest, Inc., and ProAxsis Limited, among others.

Sector

Investment Management & Fund Operators

Calendar

25/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Venture Capital

	1st Jan change	Capi.
NETSCIENTIFIC PLC	+15.00%	20.99M
HERCULES CAPITAL, INC.	+16.17%	3.1B
UMBRA COMPANIES INC.	+12.82%	1.77B
HBM HEALTHCARE INVESTMENTS AG	+9.42%	1.52B
OCTOPUS TITAN VCT PLC	-11.54%	1.2B
MOLTEN VENTURES PLC	+20.14%	771M
CION INVESTMENT CORPORATION	+10.08%	671M
VERUSA HOLDING	+32.36%	562M
OCTOPUS APOLLO VCT PLC	-4.17%	505M
WOORI TECHNOLOGY INVESTMENT CO., LTD	+30.75%	472M

Venture Capital